Published in Curr Opin Organ Transplant on June 01, 2014
Extensive multifocal branch duct IPMN of the pancreas after liver transplantation: is surgery justified? Eur J Med Res (2015) 1.40
Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives. World J Hepatol (2015) 0.91
Liver transplant patients have a risk of progression similar to that of sporadic patients with branch duct intraductal papillary mucinous neoplasms. Liver Transpl (2014) 0.83
Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation. World J Hepatol (2015) 0.82
Maintenance of normal blood pressure is dependent on IP3R1-mediated regulation of eNOS. Proc Natl Acad Sci U S A (2016) 0.79
Review on immunosuppression in liver transplantation. World J Hepatol (2015) 0.79
Insulin-Like Growth Factor I (IGF-I) Expressed from an AAV1 Vector Leads to a Complete Reversion of Liver Cirrhosis in Rats. PLoS One (2016) 0.79
Management of immunosuppressant agents following liver transplantation: Less is more. World J Hepatol (2016) 0.78
Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol (2017) 0.78
Neoplastic disease after liver transplantation: Focus on de novo neoplasms. World J Gastroenterol (2015) 0.77
Incidence, risk factors and outcome of de novo tumors in liver transplant recipients focusing on alcoholic cirrhosis. World J Hepatol (2015) 0.76
Efficient generation of hepatic cells from mesenchymal stromal cells by an innovative bio-microfluidic cell culture device. Stem Cell Res Ther (2016) 0.75
Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients: A Single-Institute Study. Biomed Res Int (2015) 0.75
Betel quid chewing leads to the development of unique de novo malignancies in liver transplant recipients, a retrospective single center study in Taiwan. Medicine (Baltimore) (2016) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
mTOR signaling in growth control and disease. Cell (2012) 29.21
Management of hepatocellular carcinoma. Hepatology (2005) 27.42
Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet (2007) 11.06
Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer (2008) 6.13
Spectrum of cancer risk among US solid organ transplant recipients. JAMA (2011) 4.99
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
The end of AIDS: HIV infection as a chronic disease. Lancet (2013) 3.96
Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet (1998) 3.77
Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology (2010) 3.54
Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science (2010) 3.08
Cancer immunoediting from immune surveillance to immune escape. Immunology (2007) 3.03
TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol (2010) 2.61
Increased cancer risk after liver transplantation: a population-based study. J Hepatol (2001) 2.25
Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer (2008) 2.24
Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol (2012) 2.15
Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database. Liver Transpl (2012) 2.14
Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl (2005) 2.04
Risk of malignant neoplasms after liver transplantation: a population-based study. Liver Transpl (2008) 1.97
Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant (2012) 1.88
Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant (2008) 1.86
Liver transplantation and subsequent risk of cancer: findings from a Canadian cohort study. Liver Transpl (2008) 1.78
Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. Am J Transplant (2011) 1.75
Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant (2010) 1.64
Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. Liver Transpl (2010) 1.59
Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology (1998) 1.41
Tacrolimus exposure after liver transplantation in randomized controlled trials: too much for too long. Am J Transplant (2013) 1.40
Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008--a Swedish population-based study. Int J Cancer (2012) 1.36
Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant (2005) 1.33
Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl (2009) 1.22
Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg (2008) 1.22
Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl (2008) 1.18
Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl (2012) 1.18
Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther (2012) 1.17
mTOR, linking metabolism and immunity. Semin Immunol (2013) 1.17
Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation (2003) 1.16
Cancer and viral infections in immunocompromised individuals. Int J Cancer (2009) 1.12
Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J Hepatol (2008) 1.10
De novo internal neoplasms after liver transplantation: increased risk and aggressive behavior in recent years? Am J Transplant (2004) 1.09
Burden of de novo malignancy in the liver transplant recipient. Liver Transpl (2012) 1.07
De Novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. Liver Transpl (2005) 1.07
Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. Transplantation (2010) 1.06
Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant (2006) 1.06
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer (2010) 1.06
Incidence of cancers following orthotopic liver transplantation in a single center: comparison with national cancer incidence rates for England and Wales. Transplantation (2005) 1.05
Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells. Cancer Res (2009) 1.04
Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant (2007) 1.04
Sirolimus conversion for patients with posttransplant Kaposi's sarcoma. Am J Transplant (2006) 1.03
Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria. Transplant Proc (2008) 1.03
Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. Aliment Pharmacol Ther (2010) 1.02
A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl (2007) 1.02
Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant (2006) 1.01
Comparison of de novo tumours after liver transplantation with incidence rates from Italian cancer registries. Dig Liver Dis (2009) 1.01
Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol (2013) 1.00
Nonmelanoma skin cancer after renal transplantation: a single-center experience in 1736 transplantations. Int J Dermatol (2011) 1.00
Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis. Am J Transplant (2012) 0.99
Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol (2005) 0.95
Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes. Transpl Int (2009) 0.95
Incidence and long-term risk of de novo malignancies after liver transplantation with implications for prevention and detection. Liver Transpl (2013) 0.92
De novo malignancy post-liver transplantation: a single center, population controlled study. Clin Transplant (2013) 0.91
Present state of immunosuppressive therapy in liver transplant recipients. Liver Transpl (2011) 0.90
Immunosuppressive therapy and tolerance of organ allografts. N Engl J Med (2008) 0.88
Multiple forms of DNA damage caused by UVA photoactivation of DNA 6-thioguanine. Photochem Photobiol (2011) 0.87
Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin. Transpl Int (2007) 0.86
Burkitt lymphoma risk in U.S. solid organ transplant recipients. Am J Hematol (2013) 0.86
Early tacrolimus exposure after liver transplantation: relationship with moderate/severe acute rejection and long-term outcome. J Hepatol (2012) 0.86
Post-transplantation malignancy: a cell autonomous mechanism with implications for therapy. Trans Am Clin Climatol Assoc (2009) 0.83
Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes. Gut (2013) 0.82
Completely steroid-free immunosuppression in liver transplantation: a randomized study. Clin Transplant (2013) 0.81
Induction immunosuppression in liver transplantation: a review. Transpl Int (2013) 0.80
From immunosuppression to immunomodulation: current principles and future strategies. Pathobiology (2013) 0.78
Allograft and overall survival of patients with posttransplant skin cancer. Dermatol Surg (2011) 0.77
Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med (2005) 6.31
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol (2006) 3.65
Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology (2009) 3.28
Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology (2013) 2.64
Transjugular liver biopsy--indications, adequacy, quality of specimens, and complications--a systematic review. J Hepatol (2007) 2.52
Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet (2011) 2.50
Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol (2010) 2.41
EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol (2011) 2.37
Comparison of the sequential organ failure assessment score with the King's College Hospital criteria and the model for end-stage liver disease score for the prognosis of acetaminophen-induced acute liver failure. Liver Transpl (2012) 2.32
A comparison between two strategies for monitoring hepatic function during antituberculous therapy. Am J Respir Crit Care Med (2011) 2.22
TIPS for refractory ascites: a single-centre experience. J Gastroenterol (2009) 2.19
Inflammation-based scores do not predict post-transplant recurrence of hepatocellular carcinoma in patients within Milan criteria. Liver Transpl (2014) 2.11
Development of a modified sampling and calculation method for isotope plasma clearance assessment of the glomerular filtration rate in patients with cirrhosis and ascites. Nucl Med Commun (2013) 2.06
Splanchnic vein thrombosis in myeloproliferative neoplasms. Br J Haematol (2013) 2.04
A randomized study comparing ligation with propranolol for primary prophylaxis of variceal bleeding in candidates for liver transplantation. Liver Transpl (2007) 2.01
Different methods of creatinine measurement significantly affect MELD scores. Liver Transpl (2007) 1.87
A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation. Liver Transpl (2006) 1.73
How to prevent varices from bleeding: shades of grey--the case for nonselective beta blockers. Gastroenterology (2007) 1.70
Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl (2007) 1.68
Liver transplantation for acute liver failure in Europe: outcomes over 20 years from the ELTR database. J Hepatol (2012) 1.66
Prognostic models in cirrhotics admitted to intensive care units better predict outcome when assessed at 48 h after admission. J Gastroenterol Hepatol (2007) 1.64
Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology (2011) 1.63
Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? Gut (2011) 1.61
Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl (2005) 1.58
The relationship between liver disease stage and liver fibrosis: a tangled web. Histopathology (2010) 1.56
Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes. J Hepatol (2012) 1.56
Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy. Liver Transpl (2009) 1.55
Critical illness-related corticosteroid insufficiency in patients with cirrhosis and variceal bleeding. Clin Gastroenterol Hepatol (2011) 1.49
Hemostasis in patients with acute kidney injury secondary to acute liver failure. Kidney Int (2013) 1.43
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin (2006) 1.38
Targeting portal pressure measurements: a critical reappraisal. Hepatology (2004) 1.36
Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts. J Infect Dis (2002) 1.33
Antibodies against homologous microbial caseinolytic proteases P characterise primary biliary cirrhosis. J Hepatol (2002) 1.24
Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol (2010) 1.23
Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis. Hepatology (2008) 1.21
Surgical repair of umbilical hernias in cirrhosis with ascites. Am J Med Sci (2011) 1.17
Bacterial infection in cirrhosis impairs coagulation by a heparin effect: a prospective study. J Hepatol (2002) 1.16
Transarterial therapies for hepatocellular carcinoma (HCC): a long way towards standardization. J Hepatol (2012) 1.15
Methods to decrease blood loss and transfusion requirements for liver transplantation. Cochrane Database Syst Rev (2011) 1.15
IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients. Obes Surg (2007) 1.15
Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl (2008) 1.14
Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. Clin Gastroenterol Hepatol (2009) 1.14
New therapeutic paradigm for patients with cirrhosis. Hepatology (2012) 1.10
Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver Int (2011) 1.10
Immunosuppression and HCV recurrence after liver transplantation. J Hepatol (2011) 1.09
RIFLE classification as predictive factor of mortality in patients with cirrhosis admitted to intensive care unit. J Gastroenterol Hepatol (2009) 1.08
Cure of Acanthamoeba cerebral abscess in a liver transplant patient. Liver Transpl (2008) 1.08
Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study. Hepatology (2013) 1.07
Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. J Hepatol (2004) 1.06
Prioritization for liver transplantation. Nat Rev Gastroenterol Hepatol (2010) 1.05
Update on the classification, assessment of prognosis and therapy of Budd-Chiari syndrome. Nat Clin Pract Gastroenterol Hepatol (2005) 1.04
Cirrhotics admitted to intensive care unit: the impact of acute renal failure on mortality. Eur J Gastroenterol Hepatol (2009) 1.04
TIPS for acute and chronic Budd-Chiari syndrome: a single-centre experience. J Hepatol (2003) 1.03
Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its Lactobacillus mimic. Hepatology (2005) 1.03
Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol (2013) 1.00
Adrenocortical dysfunction in liver disease: a systematic review. Hepatology (2012) 0.99
Management of varices in patients with cirrhosis. Nat Rev Gastroenterol Hepatol (2013) 0.99
Diagnosis and management of bacterial infections in decompensated cirrhosis. World J Hepatol (2013) 0.99
Incarcerated umbilical hernia after large volume paracentesis for refractory ascites. J Gastrointestin Liver Dis (2010) 0.99
Validation of the donor risk index in orthotopic liver transplantation within the Eurotransplant region. Liver Transpl (2012) 0.99
Assessment of fibrosis and cirrhosis in liver biopsies: an update. Semin Liver Dis (2011) 0.99
Liver transplantation and recurrent hepatocellular carcinoma: predictive value of nodule size in a retrospective and explant study. Transplantation (2006) 0.98
Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C. Hepatology (2014) 0.98
Should we routinely measure portal pressure in patients with cirrhosis, using hepatic venous pressure gradient (HVPG) as a guide for prophylaxis and therapy of bleeding and rebleeding? No. Eur J Intern Med (2010) 0.97
Epithelial colonies cultured from human explanted liver in subacute hepatic failure exhibit hepatocyte, biliary epithelial, and stem cell phenotypic markers. Stem Cells (2003) 0.97
The role of E. coli infection in the pathogenesis of primary biliary cirrhosis. Dis Markers (2010) 0.96
Liver transplantation for Budd-Chiari syndrome: A European study on 248 patients from 51 centres. J Hepatol (2005) 0.96
Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment. Semin Oncol (2010) 0.95
TACE versus TAE as therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther (2008) 0.95
A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. J Infect Dis (2004) 0.94
Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. Am J Transplant (2003) 0.94
Exploring the bidirectional interactions between human cytomegalovirus and hepatitis C virus replication after liver transplantation. Liver Transpl (2007) 0.93
Sustained, spontaneous disappearance of serum HCV-RNA under immunosuppression after liver transplantation for HCV cirrhosis. J Hepatol (2005) 0.93
Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization. J Immunol (2007) 0.93
The use of fatty liver grafts in modern allocation systems: risk assessment by the balance of risk (BAR) score. Ann Surg (2012) 0.93
Can non-invasive measurements aid clinical assessment of volume in patients with cirrhosis? World J Hepatol (2013) 0.92
Current management of hepatitis B virus infection before and after liver transplantation. Liver Int (2009) 0.92
Acute liver failure caused by diffuse hepatic melanoma infiltration. J Hepatol (2002) 0.92
Thromboelastography with citrated blood: comparability with native blood, stability of citrate storage and effect of repeated sampling. Blood Coagul Fibrinolysis (2004) 0.92
Hepatocellular carcinoma. N Engl J Med (2012) 0.91
Autoimmunity and environment: am I at risk? Clin Rev Allergy Immunol (2012) 0.91
Modelling cytomegalovirus replication patterns in the human host: factors important for pathogenesis. Proc Biol Sci (2006) 0.90
Tracking the source of the hepatitis B virus-specific CD8 T cells during lamivudine treatment. J Infect Dis (2003) 0.90
Antiviral therapy for recurrent liver graft infection with hepatitis C virus. Cochrane Database Syst Rev (2010) 0.89
Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation. J Hepatol (2012) 0.89
Cytoprotective properties of alpha-tocopherol are related to gene regulation in cultured D-galactosamine-treated human hepatocytes. Free Radic Biol Med (2007) 0.89
Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. Cochrane Database Syst Rev (2015) 0.89
Transarterial therapies for hepatocellular carcinoma. Recent Results Cancer Res (2013) 0.89
Targeting hepatoma using nitric oxide donor strategies. Antioxid Redox Signal (2012) 0.89
Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension. J Hepatol (2009) 0.89
Urinary tract infection as a risk factor for autoimmune liver disease: from bench to bedside. Clin Res Hepatol Gastroenterol (2011) 0.89
Noninvasive tests for evaluation of fibrosis in HCV recurrence after liver transplantation: a systematic review. Transpl Int (2010) 0.89
Late hepatic artery thrombosis after orthotopic liver transplantation. Liver Transpl (2003) 0.88
Novel inflammatory biomarkers of portal pressure in compensated cirrhosis patients. Hepatology (2014) 0.88
Validation of Tikhonov adaptively regularized gamma variate fitting with 24-h plasma clearance in cirrhotic patients with ascites. Eur J Nucl Med Mol Imaging (2011) 0.88
Assessment of blood coagulation in severe liver disease using thromboelastography: use of citrate storage versus native blood. Blood Coagul Fibrinolysis (2003) 0.88
A comparison of four- versus three-pass transjugular biopsy using a 19-G Tru-Cut needle and a randomized study using a cassette to prevent biopsy fragmentation. Cardiovasc Intervent Radiol (2008) 0.88
Liver transplant for adult hemophagocytic lymphohistiocytosis: case report and literature review. Exp Clin Transplant (2012) 0.88
BNP as marker of heart dysfunction in patients with liver cirrhosis. Eur J Gastroenterol Hepatol (2010) 0.88